Another complement C5-inhibitor, ravulizumab, has been approved for the treatment of PNH in the US and Europe and maintains a sustained inhibition of complement for 8 weeks following intravenous infusion. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.